Answers are grounded in this paper and cite their sources.
Interleukin-12 (IL-12) stimulates natural killer (NK) and T cell production of interferon gamma (IFN-γ), but adverse events from NK cell activation have limited its clinical use. This study shows the impact of half-life-extended, full (IL-12Fc) and partial (IL-12 3x AlaFc) IL-12 agonists on the immune system. In naive mice, serial treatment with IL-12Fc induces systemic IFN-γ, multi-organ pathology, and alterations in myelopoiesis. IL-12 Fc stimulates NK cell production of IFN-γ but also activates CD4 + , CD8 + T, and NKT cells. IL-12 Fc's ability to enhance the production of IFN-γ facilitates myelopoiesis, but IFN-γ is not required for the development of systemic toxicity. In contrast, IL-12 3x Ala Fc avoids overt disease, activates CD4 + and CD8 + T cells, and induces myelopoiesis. These differential activities were harnessed to enhance resistance to infection, indicating that a threshold of IL-12 signaling is tolerated under steady-state conditions and that fine-tuning IL-12 agonism can bolster resistance without triggering pathology.
No takes yet. Share an insight, caveat, or question.
Lanzar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: